logo
Extensively Drug-Resistant TB Outcomes Remain Poor in Europe

Extensively Drug-Resistant TB Outcomes Remain Poor in Europe

Medscape5 days ago
TOPLINE:
Only four out of 10 patients with extensively drug-resistant tuberculosis in Europe achieved successful treatment outcomes, a rate markedly lower than that for other forms of drug-resistant tuberculosis and comparable with cure rates from the pre-antibiotic era.
METHODOLOGY:
Researchers conducted a retrospective observational cohort study across 16 countries of the World Health Organization (WHO) European Region to evaluate treatment outcomes in 188 patients (median age, 42 years; 79.3% men) with extensively drug-resistant tuberculosis.
Data collected included patient characteristics, disease localisation, prior treatments, phenotypic and genotypic drug susceptibility testing results, and treatment regimens.
Treatment outcomes were categorised as successful, failure (microbiological or clinical reasons including regimen changes), lost to follow-up (treatment interrupted for 2 or more months), or not evaluated.
TAKEAWAY:
Among the 188 patients with extensively drug-resistant tuberculosis, 48.4%, 34.0%, and 17.6% of Mycobacterium tuberculosis strains were resistant to bedaquiline alone, linezolid alone, and both drugs, respectively.
Among 156 patients with available data for treatment outcomes, 40.2% (95% CI, 28.4%-53.2%) achieved successful outcomes in a pooled analysis accounting for between-country heterogeneity.
Patients with extensively drug-resistant tuberculosis had lower pooled success rates (P < .0001) and significantly higher pooled rates of treatment failure and death (P < .0001 and P = .008, respectively) than those with multidrug-/rifampicin-resistant or preextensively drug-resistant tuberculosis.
The likelihood of an unsuccessful outcome decreased with each additional effective drug in the regimen (P = .026) but increased among patients treated in upper-middle-income countries compared with that among those treated in high-income countries (P < .001).
IN PRACTICE:
"[The study] findings underscore the need for improved, rapid DST [drug susceptibility testing] tools and effective, shorter treatment regimens for extensively drug-resistant tuberculosis," the authors wrote.
SOURCE:
This study was led by Yousra Kherabi, Bichat-Claude Bernard Hospital, Assistance Publique-Hôpitaux de Paris, Université Paris Cité, Paris, France, and Ole Skouvig Pedersen, Aarhus University Hospital, Aarhus, Denmark. It was published online on July 15, 2025, in The Lancet Regional Health - Europe.
LIMITATIONS:
The coverage of the WHO European Region was limited. Most of the participating centres were specialist or referral centres, which may have introduced selection bias and limiting generalisability. Although the use of WHO-defined outcomes simplified data collection, it constrained a detailed understanding of treatment failures. Moreover, individual-level data were available only for patients with extensively drug-resistant tuberculosis, which may have introduced confounding from unmeasured patient-level factors.
DISCLOSURES:
This study did not receive any funding. One author reported serving as a co-principal investigator of clinical trials testing new regimens for multidrug-resistant tuberculosis, and some authors reported receiving honoraria for speaking engagements or serving on advisory boards of various pharmaceutical companies.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Pfizer (PFE) Receives CHMP Recommendation For Adapted COVID-19 Vaccine COMIRNATY
Pfizer (PFE) Receives CHMP Recommendation For Adapted COVID-19 Vaccine COMIRNATY

Yahoo

timean hour ago

  • Yahoo

Pfizer (PFE) Receives CHMP Recommendation For Adapted COVID-19 Vaccine COMIRNATY

BioNTech SE and Pfizer recently received a positive recommendation from the European Medicines Agency for marketing authorization of their COVID-19 vaccine, which likely contributed to Pfizer's share price increase of 8% in the last quarter. The company's advancements in COVID-19 vaccine development, alongside other product-related announcements like the XTANDI and BRAFTOVI trial results, added weight to this upward movement. Despite legal challenges and declining earnings, Pfizer's focus on innovation and strategic partnerships like the one with XtalPi possibly countered broader market moves, which saw a smaller 1% increase in the same period. We've identified 3 warning signs for Pfizer that you should be aware of. Trump's oil boom is here — pipelines are primed to profit. Discover the 22 US stocks riding the wave. The recent positive recommendation from the European Medicines Agency for the COVID-19 vaccine developed by BioNTech SE and Pfizer has contributed to an 8% increase in Pfizer's share price over the last quarter. This news may provide a temporary boost to Pfizer's revenue and earnings forecasts, especially as the company continues to innovate amidst legal challenges and declining earnings. The authorization could enhance immediate market confidence in Pfizer's product pipeline, impacting future revenue projections positively. Over the past year, Pfizer experienced a total return of 13.78% including dividends, reflecting a challenging period for shareholders. When compared to the broader US market's return of 17.2% over the same period, Pfizer has underperformed, highlighting investor concerns over competitive pressures and revenue growth prospects. The current share price movement toward the analyst consensus price target of $29.23 suggests a cautiously optimistic outlook among some market participants. Analysts' revenue forecasts reflect potential declines due to increased competition for existing products, yet others anticipate that strategic shifts in research focus, especially in oncology, might mitigate future earnings risks. With a modest increase of 8% in shares largely tied to vaccine authorization, it underscores the uncertainty surrounding longer-term performance relative to bearish analyst expectations. Understand Pfizer's track record by examining our performance history report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include PFE. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@

Sir David Nabarro, WHO's special envoy for Covid-19, dies aged 75
Sir David Nabarro, WHO's special envoy for Covid-19, dies aged 75

Yahoo

time3 hours ago

  • Yahoo

Sir David Nabarro, WHO's special envoy for Covid-19, dies aged 75

Sir David Nabarro, who was the World Health Organisation's (WHO) special envoy for Covid-19, has died aged 75. The WHO's director-general Dr Tedros Adhanom Ghebreyesus said he was 'deeply shocked and saddened by the passing' of Sir David. London-born Sir David worked at the United Nations for 17 years, expanding nutrition programmes to underdeveloped countries and tackling health crises including outbreaks of malaria, bird flu and Ebola, before leaving in 2017. He was appointed as special envoy on Covid-19 for the WHO in 2020 and appeared on news programmes regularly throughout the pandemic, telling Sky News in June 2021 that humanity was going to have to learn how to 'co-exist' with Covid-19. Sir David was knighted at Buckingham Palace in March 2023 for his outstanding contribution to global health. Dr Tedros wrote on X: 'Deeply shocked and saddened by the passing of our dear friend, colleague and WHO Envoy David Nabarro. 'David was a great champion of global health and health equity, and a wise, generous mentor to countless individuals. 'His work touched and impacted so many lives across the world. 'On behalf of WHO, I'm extending our heartfelt condolences to David's family, friends and colleagues. 'Rest in peace, my dear friend. We will dearly miss your expertise, wisdom and kindness.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store